Notification That Annual Report Will Be Submitted Late (nt 10-k)

Date : 02/28/2019 @ 11:30AM
Source : Edgar (US Regulatory)
Stock : Gala Pharmaceutical Inc (PK) (GLPH)
Quote : 0.01  0.00192 (23.76%) @ 8:00PM

Notification That Annual Report Will Be Submitted Late (nt 10-k)

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

  OMB APPROVAL
  OMB Number: 3235-0058
Expires: August 31, 2015
Estimated average burden
hours per response.... 2.50
   
  SEC FILE NUMBER
333-172744
   
  CUSIP NUMBER
36316C106

 

(Check one):   ☒  Form 10-K     ☐  Form 20-F      ☐ Form 11-K      ☐ Form 10-Q     ☐  Form 10-D     ☐  Form N-SAR     ☐  Form N-CSR

 

  For Period Ended: November 30, 2018
   
 

☐   Transition Report on Form 10-K   

☐   Transition Report on Form 20-F    

☐   Transition Report on Form 11-K    

☐   Transition Report on Form 10-Q    

☐   Transition Report on Form N-SAR

   
  For the Transition Period Ended:_____________

 

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

GALA PHARMACEUTICAL, INC.

Full Name of Registrant

 

N/A
Former Name if Applicable

 

18881 Von Karman Ave., Suite 1440

Address of Principal Executive Office (Street and Number)

 

Irvine, CA 92612

City, State and Zip Code

 

 

 

 

 

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)

 

x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
   
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The company’s auditor will complete their review of the financial information approximately March 12, 2019.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

  Owen Naccarato 949 851-9261
  (Name) (Area Code) (Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ?  If answer is no, identify report(s).

 

☒ Yes   ☐ No

   
(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

☐ Yes   ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

GALA PHARMACEUTICAL, INC.
(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

     
Date: February 27, 2019 By: /s/ Maqsood Rehman
    Maqsood Rehman
    Title: Chief Executive Officer

 

 

 

 

Gala Pharmaceutical (PK) (USOTC:GLPH)
Historical Stock Chart

1 Year : From Mar 2019 to Mar 2020

Click Here for more Gala Pharmaceutical (PK) Charts.

Gala Pharmaceutical (PK) (USOTC:GLPH)
Intraday Stock Chart

Today : Sunday 29 March 2020

Click Here for more Gala Pharmaceutical (PK) Charts.

Latest GLPH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


$
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.